Clementia Pharmaceuticals (CMTA) Receives Daily News Impact Rating of 0.21
Media headlines about Clementia Pharmaceuticals (NASDAQ:CMTA) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Clementia Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.1278585207855 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Clementia Pharmaceuticals (CMTA) opened at $20.02 on Monday. The stock has a market cap of $645.06 and a PE ratio of -3.91. Clementia Pharmaceuticals has a 52-week low of $15.05 and a 52-week high of $20.08.
CMTA has been the topic of several research reports. Morgan Stanley initiated coverage on shares of Clementia Pharmaceuticals in a report on Monday, August 28th. They issued an “overweight” rating and a $27.00 price objective on the stock. Wedbush initiated coverage on shares of Clementia Pharmaceuticals in a report on Monday, August 28th. They issued an “outperform” rating and a $26.00 price objective on the stock. Leerink Swann initiated coverage on shares of Clementia Pharmaceuticals in a research report on Monday, August 28th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, BTIG Research initiated coverage on shares of Clementia Pharmaceuticals in a research report on Thursday, August 31st. They issued a “buy” rating and a $32.00 target price for the company.
About Clementia Pharmaceuticals
Clementia Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate, palovarotene, is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist), and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models.
Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.